DX9.F Stock Analysis
DX
Uncovered
Deltex Medical Group PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Deltex Medical Group Plc engages in manufacturing and sale of advanced haemodynamic monitoring technologies. The company is headquartered in Chichester, West Sussex and currently employs 46 full-time employees. The company went IPO on 2001-08-20. The firm develops and manufactures specialist hemodynamics monitoring devices. The firm's TrueVue platform offers three monitoring technologies, such as Oesophageal Doppler Monitoring (ODM+), Pulse Pressure Waveform Analysis (PPWA) and High Definition Impedance CardioGraphy (HD-ICG). ODM+ guides fluid and drug interventions in real-time and keeps surgical patients in a haemodynamic state. PPWA uses the researched pulse pressure wave algorithm, which is available to derive haemodynamic parameters, calibrated from the Doppler. HD-ICG provides continuous and sensitive measurements of cardiac output and other haemodynamic parameters. The Company’s applications include COVID-19 critical care, surgery, acute kidney injury, enhanced recovery and paediatric. Its commercial activities are around three divisions: the United Kingdom, the United States and International.